C18-Ceramide

• Description:

  C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology[1][2].

• UNSPSC:

  12352211

• Target:

  Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/c18-ceramide.html

• Purity:

  99.95

• Solubility:

  DMF : 1 mg/mL (ultrasonic) |DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 10 mg/mL (ultrasonic)

• Smiles:

  CCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O

• Molecular Formula:

  C36H71NO3

• Molecular Weight:

  565.95

• References & Citations:

  [1]Tang N, et al. Differential effects of ceramide species on exocytosis in rat PC12 cells. Exp Brain Res. 2007 Nov;183 (2) :241-7.|[2]Wang Z, et al. Overexpression of ceramide synthase 1 increases C18-ceramide and leads to lethal autophagy in human glioma. Oncotarget. 2017 Oct 23;8 (61) :104022-104036.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2304-81-6]